浸润性小叶癌与导管癌的BRCA1/2突变关联系统综述与荟萃分析
该系统综述与荟萃分析纳入12项研究共8004例乳腺癌女性,比较浸润性小叶癌(ILC)与浸润性导管癌(IDC)的胚系BRCA1/2突变频率。BRCA1突变在ILC中显著低于IDC(SOR=0.32,95%CI 0.16-0.65),BRCA2总体无显著关联(SOR=1.28,95%CI 0.95-1.72),但排除高偏倚风险研究后BRCA2突变在ILC中更常见(SOR=2.56,95%CI 1.15-5.7)。
要点
- BRCA1突变在IDC中更常见,尤其在年轻及有乳腺癌家族史患者。
- BRCA2总体与组织学亚型无显著关联,但低偏倚研究中ILC的BRCA2突变更频繁。
- BRCA1与BRCA2的关联差异具有统计学意义(p<0.001)。
核心结论
- 在低偏倚风险研究中,胚系BRCA2突变在ILC患者中比IDC更常见。
- BRCA1突变在IDC中更常见,尤其在年轻及有乳腺癌家族史的患者中。
研究设计与样本
- 系统文献检索后纳入12项发表于1998至2025年的研究,共8004例乳腺癌女性。
- 采用随机效应单变量与双变量模型计算汇总比值比(SOR)及95%CI,并通过荟萃回归和亚组分析探讨异质性。
主要发现
- BRCA1突变在ILC中显著少于IDC(SOR=0.32,95%CI 0.16-0.65)。
- BRCA2突变总体与组织学亚型无显著关联(SOR=1.28,95%CI 0.95-1.72)。
- BRCA1与BRCA2的关联差异有统计学意义(p<0.001)。
- BRCA1的发表偏倚检验无显著提示(Egger's p=0.23,Begg's p=0.12)。
- 研究间异质性BRCA1为29%,BRCA2为0%。
关键数值与推荐
- 排除高偏倚风险研究后,BRCA2突变在ILC中更频繁(SOR=2.56,95%CI 1.15-5.7)。
- 该关联主要由考虑BRCA1与BRCA2估计相关性的双变量随机效应模型驱动。
临床怎么用
- 对ILC患者应关注BRCA2胚系突变风险,尤其在高偏倚风险较低的研究背景下。
- 对IDC患者,尤其年轻及有乳腺癌家族史者,应关注BRCA1胚系突变风险。
局限性
- 纳入研究间存在异质性(BRCA1为29%),可能影响合并估计。
- BRCA2的关联结果受偏倚风险及统计模型选择影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Invasive lobular breast carcinoma (ILC) differs from invasive ductal breast carcinoma (IDC) with respect to genetic alterations and risk factors. We aimed to quantify differences in the prevalence of germline BRCA1/2 mutations between these two patients' populations. MATERIALS AND METHODS: We conducted a systematic literature search to extract data on the association between BRCA1/2 mutation status and breast cancer (BC) histological subtype (ILC and IDC). Summary odds ratios (SOR) and 95% CI were calculated using random effects univariate and bivariate models and between-study heterogeneity investigated through meta-regression and subgroup analyses. RESULTS: Twelve studies, published between 1998 and 2025, were considered, including 8004 BC women. BRCA1 mutations were significantly less frequent in patients with ILC than IDC (SOR=0.32, 95%CI (0.16-0.65)) whereas no association was found overall for BRCA2 (SOR=1.28, 95%CI (0.95-1.72)). The difference between the association with BRCA1 and BRCA2 was statistically significant (p-value<0.001). There was no indication of publication bias in BRCA1 (Egger's and Begg's test p-value=0.23, 0.12). The between study heterogeneity was 29% in BRCA1 and 0% in BRCA2. Excluding papers with high risk of bias, BRCA2 mutations were more frequent in patients with ILC than in IDC (SOR=2.56, 95%CI (1.15-5.7)). This association was primarily driven by the bivariate random-effects model, which accounts for the correlation between BRCA1 and BRCA2 estimates. CONCLUSIONS: In studies with lower risk of bias, germline BRCA2 mutations were more frequent in patients with ILC than IDC. Conversely, BRCA1 mutations are more frequently observed in IDC, particularly among younger patients and those with a positive family history of BC.
引用
- Corso G, Andreon C, La Vecchia C, et al. Invasive lobular and ductal breast cancers: a systematic review and metanalysis in association with BRCA1/2 mutation status. Eur J Cancer. 2026. PMID: 41930855. doi:10.1016/j.ejca.2026.116692
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。